GlassScriptPhysician profile
James P Brodeur
NPI 1184620940
$5,453.18
in general payments reported to CMS, 2019-2025
26 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $488 · 2021: $582 · 2022: $1,000 · 2023: $1,140 · 2024: $734 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.93 | 2019-2025 | Rinvoq, Humira |
| Pfizer INC. | $785.41 | 2019-2025 | |
| Amgen INC. | $599.21 | 2019-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $549.23 | 2019-2025 | Tremfya |
| Ucb, INC. | $453.69 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $205.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $200.17 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $195.75 | 2021-2023 | Acthar |
| Glaxosmithkline, LLC. | $182.98 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $179.02 | 2020-2023 | Taltz |
| Genentech USA, INC. | $164.88 | 2019-2025 | Actemra |
| Cumberland Pharmaceuticals, INC. | $122.80 | 2022-2023 | Reditrex |
| Aurinia Pharma U.S., INC. | $100.24 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $71.66 | 2023-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $67.35 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $65.29 | 2023-2025 | Hyrimoz |
| Genzyme Corporation | $47.44 | 2023-2024 | |
| Kyowa Kirin, INC. | $45.53 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $43.11 | 2024-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $23.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.59 | 2022 | |
| Biodelivery Sciences International, INC. | $19.13 | 2020 | |
| Horizon Therapeutics Plc | $17.52 | 2022 | |
| Radius Health, INC. | $14.68 | 2019 | |
| Medexus Pharma, INC. | $14.20 | 2019 | |
| Organon LLC | $13.44 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brodeur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.